BioInformant

Your Global Leader in Stem Cell Market Research

Home » iPSC » Page 14

Technical Attributes You Need to Know Invest in the Induced Pluripotent Stem Cell (iPSC) Market

By Leave a Comment

If you are an investor considering an opportunity related to induced pluripotent stem cells (iPSCs), the market can initially appear technical and confusing. However, if you focus on a few key points of understanding, you’ll be able to assess the technical attributes that matter, including what defines the cell type, advantages and disadvantages, key events driving market growth, and opportunities for commercialization.

To begin, the best place to start is with a clear definition of the cell type.

Definition of Induced Pluripotent Stem Cells

Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell artificially derived from a non-pluripotent cell – typically an adult somatic cell, by inducing a ‘forced’ expression of specific gene. [Read more…]

Induced Pluripotent Stem Cell News Round-Up| February 22 – 28, 2015

By Leave a Comment

“Supreme Court Rules on Stem Cells, $100 Billion Proposed for International Stem Cell Collaboration, Japan to Launch iPSC Therapy Center, and More”

Induced pluripotent stem cells (iPSCs) are a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. More recently, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued in February 2015.
[Read more…]

Induced Pluripotent Stem Cell (iPSC) News Round-Up| February 2015

By Leave a Comment

“Supreme Court Rules on Stem Cells, $100 Billion Proposed for International Stem Cell Collaboration, Japan to Launch iPSC Therapy Center, and More”

Induced pluripotent stem cells (iPSCs) are a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. More recently, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued in February 2015. [Read more…]

Induced Pluripotent Stem Cell News Round-Up| February 15-22, 2015

By Leave a Comment

The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area.  Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more. [Read more…]

Induced Pluripotent Stem Cell (iSPC) News Round-Up| January 2015

By Leave a Comment

The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area.  Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more. [Read more…]

BioInformant's World-Class Clients